ClinicalTrials.gg
CompletedNCT02075281Updated Aug 9, 2016

Effect of LAPS-Exendin on Body Weight in Obese Population

A Phase 2 interventional study of HM11260C and Placebo in Obesity, sponsored by Hanmi Pharmaceutical Company Limited. Completed at 1 site in United States. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-08-09.

Sponsored by Hanmi Pharmaceutical Company Limited · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
297
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Study summary

The purpose of this study is to determine the optimal dose and regimen of HM11260C, in combination with a hypocaloric diet, to reduce weight in obese subjects who are otherwise considered in stable health.

Read the detailed description

Phase 2 study

02

Conditions studied

  • Obesity

Browse trials for

03

In context

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

This study's enrollment of 297 is above the median of 67 across 9,016 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Hanmi Pharmaceutical Company Limited is the lead sponsor of 191 studies on the registry; 12 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: 18 years to 65 years

    • Genders: male and female
    • healthy obese population
    • non-diabetes
    • stable body weight for at least 3 months prior to screening

Exclusion criteria

  • Pregnant or nursing (lactating) women

    • Drug-induced obesity
    • Diabetes mellitus (type 1, 2, and other)
    • Previous surgical treatment for obesity
    • Any known history of severe gastrointestinal (GI) disease or intolerance
    • Known history of pancreatitis with presence of raised serum amylase and lipase
    • History of suicide attempts or recent history (within 2 years prior to screening) of major depression, anxiety, or other psychiatric disease requiring treatment with prescription medication including selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitor s (SNRIs), antipsychotics, and lithium.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
297 participants (actual)

Study arms

  • Experimental
    HM11260C

    HM11260C 4 mg weekly sc injection

    Biological: HM11260C

  • Placebo comparator
    Placebo

    Placebo weekly sc injection

    Biological: Placebo

  • Experimental
    HM11260C 6 mg/week

    HM11260C 6 mg weekly sc injection

    Biological: HM11260C

  • Experimental
    HM11260C 6 mg/biweekly

    HM11260C 6 mg biweekly sc injection

    Biological: HM11260C

  • Experimental
    HM11260C 8 mg/biweekly

    HM11260C 8 mg biweekly sc injection

    Biological: HM11260C

Interventions

  • BiologicalHM11260C

    Glucagon-like peptide-1 analogue

  • BiologicalPlacebo
06

What researchers measure

Primary outcomes

  1. Change from baseline in body weight at 20 weeks

    Time frame: 20 weeks from baseline

Secondary outcomes

  1. Number of participants with adverse event

    Time frame: during 20 weeks of treatment and follow-up period

  2. Change from baseline in HbA1c and fasting plasma glucose level at 20 week

    Time frame: 20 weeks from baseline

  3. Change from baseline in blood lipid profile (e.g., cholesterol, and LDL-C level) at 20 week

    Cholesterol level, LDL-C level

    Time frame: 20 weeks from baseline

Other outcomes

  1. Change from baseline in waist circumference at 20 week

    Time frame: 20 weeks after baseline

  2. Change from baseline in β-cell function at 20 week

    homeostatic model assessment

    Time frame: 20 week from baseline

07

Study locations

1 site
  • Hanmi pharmaceutical
    Los angeles, California, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2014, a primary completion of Jan 2015 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2014
First posted
Mar 3, 2014
Start
Feb 2014
Primary completionActual
Jan 2015
CompletionActual
Feb 2015
Results delay requested
Aug 8, 2016
Last update
Aug 9, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02075281
Responsible party
Sponsor
First posted
Mar 3, 2014
Start date
Feb 2014
Primary completion
Jan 2015
Completion
Feb 2015
Last update
Aug 9, 2016

Study contacts

Hanmi pharmaceuticals Hanmi pharmaceuticals
principal investigator · Hanmi pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Efpeglenatide

Start the discussion